Programmed Death-ligand 1(PD-L1) and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced Non-small Cell Lung Cancer (NSCLC) Patients
Phase of Trial: Phase IV
Latest Information Update: 15 Oct 2017
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ATHENE
- 31 Aug 2018 Biomarkers information updated
- 15 Oct 2017 Status changed from not yet recruiting to recruiting, according to trial design presented at the 18th World Conference on Lung Cancer.
- 15 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.